<DOC>
	<DOC>NCT02525874</DOC>
	<brief_summary>The primary objective of the study is to evaluate the effect of BG00012 on lymphocyte subset counts during the first year of treatment in subjects with relapsing-remitting multiple sclerosis (RRMS). A secondary objective is to evaluate the pharmacodynamic effect on absolute lymphocyte counts (ALCs) and immunoglobulins (Igs) during the first year of treatment.</brief_summary>
	<brief_title>Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Subjects of childbearing potential (including female subjects who are postmenopausal for less than 1 year) must practice effective contraception during the study and be willing and able to continue contraception for 30 days after their last dose of study treatment. Must have a confirmed diagnosis of RRMS according to the revised McDonald criteria (2010) [Polman 2011] Key History of or positive test result at Screening for: human immunodeficiency virus hepatitis C virus antibody hepatitis B infection Drug or alcohol abuse within 1 year prior to Screening. Prior treatment with any of the following: cladribine mitoxantrone total lymphoid irradiation alemtuzumab Tcell or Tcell receptor vaccination any therapeutic monoclonal antibody, with the exception of natalizumab or daclizumab Treatment with any of the following medications or procedures within 6 months prior to Baseline (Day 1): DMF (given as FumadermÂ®) or BG00012; enrollment will be limited to no more than 40 subjects (out of 200) with prior DMF exposure cyclosporine azathioprine methotrexate mycophenolate mofetil intravenous (IV) Ig plasmapheresis or cytapheresis NOTE: Other protocol defined Inclusion/Exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Tecfidera</keyword>
	<keyword>DMF</keyword>
	<keyword>dimethyl fumarate</keyword>
</DOC>